...
首页> 外文期刊>The American Journal of the Medical Sciences >Effect of lipid levels and lipid-lowering therapy on restenosis after coronary artery stenting.
【24h】

Effect of lipid levels and lipid-lowering therapy on restenosis after coronary artery stenting.

机译:血脂水平和降脂治疗对冠状动脉支架置入术后再狭窄的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Recent experimental and clinical data suggest that lowering serum lipid levels with statins may prevent or delay the process of restenosis. The purpose of this trial is to determine whether lipid levels relate to restenosis and/or whether statin therapy can prevent or delay the process of restenosis after intracoronary stenting. METHODS: One hundred thirty-six patients who underwent single coronary artery stenting from June 1995 to June 1997 in our institution were included in the study. All these patients were followed for at least 9 months (mean 392+/-148 days) for major adverse cardiac events (MACE). We defined as MACE the occurrence of death, myocardial infarction, or need for target lesion revascularization. From this cohort, 103 patients had at least one lipid parameter from the lipid profile evaluated within 2 months from the date of the procedure. Patients who had the stent because of an acute myocardial infarction were included in the study only if their lipid profile was evaluatedbefore or at least 6 weeks after the event. Patients with triglyceride levels above 500 had both triglyceride and low-density lipoprotein cholesterol levels excluded from the statistical analysis. Patients were divided into two groups based on lipid levels: normal (Group I; n=31) and elevated (Group II; n=72). Patient outcomes were also analyzed by statin therapy use. RESULTS: There was no significant difference in MACE rates between the two groups when outcomes were analyzed by lipid levels (22.6% versus 20.8% P=0.8). Furthermore, outcomes were analyzed by use of statin therapy (Group III, n=53, on statin versus Group IV, n=50, on no statin). There was also no difference in MACE rates between the two groups (20.8% versus 22%; P=0.8). CONCLUSION: The process of restenosis has unique features that differentiate it from atherosclerosis. Although lipid-lowering therapy is crucial in delaying the process of atherosclerosis, its role in the prevention of restenosis is yet to be proven.
机译:背景:最近的实验和临床数据表明,他汀类药物降低血脂水平可以预防或延迟再狭窄的进程。该试验的目的是确定脂质水平是否与再狭窄有关和/或他汀类药物疗法是否可以预防或延迟冠状动脉内支架置入后再狭窄的过程。方法:1995年6月至1997年6月在我院进行的136例单次冠状动脉支架置入术的患者被纳入研究。所有这些患者均因重大不良心脏事件(MACE)进行了至少9个月(平均392 +/- 148天)的随访。我们将死亡,心肌梗塞或靶病变血运重建的需要定义为MACE。在该队列中,从手术日期算起的2个月内,有103名患者的脂质谱至少评估了一个脂质参数。只有在事件发生前或事件发生后至少6周评估了他们的脂质状况,才将因急性心肌梗塞而置入支架的患者纳入研究。甘油三酸酯水平高于500的患者的甘油三酸酯和低密度脂蛋白胆固醇水平均被排除在统计分析之外。根据血脂水平将患者分为两组:正常(I组; n = 31)和升高(II组; n = 72)。还通过他汀类药物的使用分析了患者的预后。结果:按血脂水平分析结局时,两组之间的MACE率无显着差异(22.6%对20.8%P = 0.8)。此外,通过使用他汀类药物疗法对结果进行了分析(第3组,他汀类药物为n = 53,第IV组,没有他汀类药物,n = 50)。两组之间的MACE率也没有差异(20.8%对22%; P = 0.8)。结论:再狭窄的过程具有与动脉粥样硬化不同的独特特征。尽管降脂疗法对于延迟动脉粥样硬化的进程至关重要,但其在预防再狭窄中的作用尚未得到证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号